PRT062607

• CAT Number: I001425
• CAS Number: 1370261-96-3
• Molecular Formula: C19H23N9O
• Molecular Weight: 393.5
• Purity: ≥95%
• Synonyms: P505-15;PRT062607;PRT2607
• Target: Syk
• Solubility: 10 mM in DMSO
• Storage: -20°C
• IC50: 1-2 nM [1]
• InChIKey: TXGKRVFSSHPBAJ-JKSUJKDBSA-N

PRT062607 (Cat.No:I001425) is a small molecule inhibitor that targets the phosphoinositide 3-kinase (PI3K) delta isoform. It has shown potential in preclinical studies for the treatment of various hematological malignancies, including chronic lymphocytic leukemia (CLL) and lymphoma. PRT062607 exhibits selective inhibition of PI3K delta, which plays a critical role in B-cell signaling pathways.

Reference

[1]. Coffey G, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340(2):350-9.
[2]. Spurgeon SE, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013 Feb;344(2):378-87.
[3]. Hoellenriegel J, et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia. 2012 Jul;26(7):1576-83.